Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: Results from STAR*D

Bradley N. Gaynes, A. John Rush, Madhukar H. Trivedi, Stephen R. Wisniewski, G. K. Balasubramani, Patrick J. McGrath, Michael E. Thase, Michael Klinkman, Andrew A. Nierenberg, William R. Yates, Maurizio Fava

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

BACKGROUND: Whether the acute outcomes of major depressive disorder (MDD) treated in primary (PC) or specialty care (SC) settings are different is unknown. OBJECTIVE: To compare the treatment and outcomes for depressed outpatients treated in primary versus specialty settings with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a broadly inclusive effectiveness trial. DESIGN: Open clinical trial with citalopram for up to 14 weeks at 18 primary and 23 specialty sites. Participants received measurement-based care with 5 recommended treatment visits, manualized pharmacotherapy, ongoing support and guidance by a clinical research coordinator, the use of structured evaluation of depressive symptoms and side effects at each visit, and a centralized treatment monitoring and feedback system. PARTICIPANTS: A total of 2,876 previously established outpatients in primary (n=1091) or specialty (n=1785) with nonpsychotic depression who had at least 1 post-baseline measure. MEASUREMENTS AND MAIN RESULTS: Remission (Hamilton Depression Rating Scale for Depression [Hamilton] or 16-item Quick Inventory of Depressive Symptomatology-Self-Rated [QIDS-SR 16]); response (QIDS-SR16); time to first remission (QIDS-SR16). Remission rates by Hamilton (26.6% PC vs 28.0% SC, p=.40) and by QIDS-SR16 (32.5% PC vs 33.1% SC, p=.78) and response rates by QIDS-SR16 (45.7% PC vs 47.6% SC, p=.33) were not different. For those who reached remission or response at exit, the time to remission (6.2 weeks PC vs 6.9 weeks SC, p=.12) and to response (5.5 weeks PC vs 5.4 weeks SC, p=.97) did not differ by setting. CONCLUSIONS: Identical remission and response rates can be achieved in primary and specialty settings when identical care is provided.

Original languageEnglish (US)
Pages (from-to)551-560
Number of pages10
JournalJournal of General Internal Medicine
Volume23
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Outpatients
Depression
Citalopram
Therapeutics
Major Depressive Disorder
Clinical Trials
Drug Therapy
Equipment and Supplies
Research

Keywords

  • Clinical trial
  • Depression
  • Outcomes
  • Primary care

ASJC Scopus subject areas

  • Internal Medicine
  • Medicine(all)

Cite this

Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care : Results from STAR*D. / Gaynes, Bradley N.; Rush, A. John; Trivedi, Madhukar H.; Wisniewski, Stephen R.; Balasubramani, G. K.; McGrath, Patrick J.; Thase, Michael E.; Klinkman, Michael; Nierenberg, Andrew A.; Yates, William R.; Fava, Maurizio.

In: Journal of General Internal Medicine, Vol. 23, No. 5, 05.2008, p. 551-560.

Research output: Contribution to journalArticle

Gaynes, BN, Rush, AJ, Trivedi, MH, Wisniewski, SR, Balasubramani, GK, McGrath, PJ, Thase, ME, Klinkman, M, Nierenberg, AA, Yates, WR & Fava, M 2008, 'Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: Results from STAR*D', Journal of General Internal Medicine, vol. 23, no. 5, pp. 551-560. https://doi.org/10.1007/s11606-008-0522-3
Gaynes, Bradley N. ; Rush, A. John ; Trivedi, Madhukar H. ; Wisniewski, Stephen R. ; Balasubramani, G. K. ; McGrath, Patrick J. ; Thase, Michael E. ; Klinkman, Michael ; Nierenberg, Andrew A. ; Yates, William R. ; Fava, Maurizio. / Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care : Results from STAR*D. In: Journal of General Internal Medicine. 2008 ; Vol. 23, No. 5. pp. 551-560.
@article{8690f51aa26b415795783b7d2f3608b4,
title = "Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: Results from STAR*D",
abstract = "BACKGROUND: Whether the acute outcomes of major depressive disorder (MDD) treated in primary (PC) or specialty care (SC) settings are different is unknown. OBJECTIVE: To compare the treatment and outcomes for depressed outpatients treated in primary versus specialty settings with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a broadly inclusive effectiveness trial. DESIGN: Open clinical trial with citalopram for up to 14 weeks at 18 primary and 23 specialty sites. Participants received measurement-based care with 5 recommended treatment visits, manualized pharmacotherapy, ongoing support and guidance by a clinical research coordinator, the use of structured evaluation of depressive symptoms and side effects at each visit, and a centralized treatment monitoring and feedback system. PARTICIPANTS: A total of 2,876 previously established outpatients in primary (n=1091) or specialty (n=1785) with nonpsychotic depression who had at least 1 post-baseline measure. MEASUREMENTS AND MAIN RESULTS: Remission (Hamilton Depression Rating Scale for Depression [Hamilton] or 16-item Quick Inventory of Depressive Symptomatology-Self-Rated [QIDS-SR 16]); response (QIDS-SR16); time to first remission (QIDS-SR16). Remission rates by Hamilton (26.6{\%} PC vs 28.0{\%} SC, p=.40) and by QIDS-SR16 (32.5{\%} PC vs 33.1{\%} SC, p=.78) and response rates by QIDS-SR16 (45.7{\%} PC vs 47.6{\%} SC, p=.33) were not different. For those who reached remission or response at exit, the time to remission (6.2 weeks PC vs 6.9 weeks SC, p=.12) and to response (5.5 weeks PC vs 5.4 weeks SC, p=.97) did not differ by setting. CONCLUSIONS: Identical remission and response rates can be achieved in primary and specialty settings when identical care is provided.",
keywords = "Clinical trial, Depression, Outcomes, Primary care",
author = "Gaynes, {Bradley N.} and Rush, {A. John} and Trivedi, {Madhukar H.} and Wisniewski, {Stephen R.} and Balasubramani, {G. K.} and McGrath, {Patrick J.} and Thase, {Michael E.} and Michael Klinkman and Nierenberg, {Andrew A.} and Yates, {William R.} and Maurizio Fava",
year = "2008",
month = "5",
doi = "10.1007/s11606-008-0522-3",
language = "English (US)",
volume = "23",
pages = "551--560",
journal = "Journal of General Internal Medicine",
issn = "0884-8734",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care

T2 - Results from STAR*D

AU - Gaynes, Bradley N.

AU - Rush, A. John

AU - Trivedi, Madhukar H.

AU - Wisniewski, Stephen R.

AU - Balasubramani, G. K.

AU - McGrath, Patrick J.

AU - Thase, Michael E.

AU - Klinkman, Michael

AU - Nierenberg, Andrew A.

AU - Yates, William R.

AU - Fava, Maurizio

PY - 2008/5

Y1 - 2008/5

N2 - BACKGROUND: Whether the acute outcomes of major depressive disorder (MDD) treated in primary (PC) or specialty care (SC) settings are different is unknown. OBJECTIVE: To compare the treatment and outcomes for depressed outpatients treated in primary versus specialty settings with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a broadly inclusive effectiveness trial. DESIGN: Open clinical trial with citalopram for up to 14 weeks at 18 primary and 23 specialty sites. Participants received measurement-based care with 5 recommended treatment visits, manualized pharmacotherapy, ongoing support and guidance by a clinical research coordinator, the use of structured evaluation of depressive symptoms and side effects at each visit, and a centralized treatment monitoring and feedback system. PARTICIPANTS: A total of 2,876 previously established outpatients in primary (n=1091) or specialty (n=1785) with nonpsychotic depression who had at least 1 post-baseline measure. MEASUREMENTS AND MAIN RESULTS: Remission (Hamilton Depression Rating Scale for Depression [Hamilton] or 16-item Quick Inventory of Depressive Symptomatology-Self-Rated [QIDS-SR 16]); response (QIDS-SR16); time to first remission (QIDS-SR16). Remission rates by Hamilton (26.6% PC vs 28.0% SC, p=.40) and by QIDS-SR16 (32.5% PC vs 33.1% SC, p=.78) and response rates by QIDS-SR16 (45.7% PC vs 47.6% SC, p=.33) were not different. For those who reached remission or response at exit, the time to remission (6.2 weeks PC vs 6.9 weeks SC, p=.12) and to response (5.5 weeks PC vs 5.4 weeks SC, p=.97) did not differ by setting. CONCLUSIONS: Identical remission and response rates can be achieved in primary and specialty settings when identical care is provided.

AB - BACKGROUND: Whether the acute outcomes of major depressive disorder (MDD) treated in primary (PC) or specialty care (SC) settings are different is unknown. OBJECTIVE: To compare the treatment and outcomes for depressed outpatients treated in primary versus specialty settings with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a broadly inclusive effectiveness trial. DESIGN: Open clinical trial with citalopram for up to 14 weeks at 18 primary and 23 specialty sites. Participants received measurement-based care with 5 recommended treatment visits, manualized pharmacotherapy, ongoing support and guidance by a clinical research coordinator, the use of structured evaluation of depressive symptoms and side effects at each visit, and a centralized treatment monitoring and feedback system. PARTICIPANTS: A total of 2,876 previously established outpatients in primary (n=1091) or specialty (n=1785) with nonpsychotic depression who had at least 1 post-baseline measure. MEASUREMENTS AND MAIN RESULTS: Remission (Hamilton Depression Rating Scale for Depression [Hamilton] or 16-item Quick Inventory of Depressive Symptomatology-Self-Rated [QIDS-SR 16]); response (QIDS-SR16); time to first remission (QIDS-SR16). Remission rates by Hamilton (26.6% PC vs 28.0% SC, p=.40) and by QIDS-SR16 (32.5% PC vs 33.1% SC, p=.78) and response rates by QIDS-SR16 (45.7% PC vs 47.6% SC, p=.33) were not different. For those who reached remission or response at exit, the time to remission (6.2 weeks PC vs 6.9 weeks SC, p=.12) and to response (5.5 weeks PC vs 5.4 weeks SC, p=.97) did not differ by setting. CONCLUSIONS: Identical remission and response rates can be achieved in primary and specialty settings when identical care is provided.

KW - Clinical trial

KW - Depression

KW - Outcomes

KW - Primary care

UR - http://www.scopus.com/inward/record.url?scp=42449088072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449088072&partnerID=8YFLogxK

U2 - 10.1007/s11606-008-0522-3

DO - 10.1007/s11606-008-0522-3

M3 - Article

C2 - 18247097

AN - SCOPUS:42449088072

VL - 23

SP - 551

EP - 560

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

SN - 0884-8734

IS - 5

ER -